EMA Authorised: Mektovi (binimetinib) — Pierre Fabre Medicament

View source ↗

Summary

The European Medicines Agency has authorised Mektovi (binimetinib) for melanoma, with Pierre Fabre Medicament as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MEKTOVI (BINIMETINIB)

Snippet

Status: Authorised. Therapeutic area: Melanoma. MAH: Pierre Fabre Medicament. Decision date: 18/09/2025